Diabetic Med:糖尿病相关的下肢截肢发病率与糖尿病足护理密切相关,且随着护理的提高而改善

2018-03-25 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于糖尿病有关的主要下肢截肢发病率与糖尿病足护理密切相关,并随着护理的提高而改善的同行评议的研究。该研究调查英格兰西南地区糖尿病相关的下肢截肢发生率与足部护理的关系。 研究于英格兰在西南某一地区引入10项足部护理服务,从2007年开始,该区域足部溃疡发病率稳定,截肢发病率持续下降。引入的服务包括行政支持,标准化普通足部筛查,改善社区足

近日,国际杂志 《Diabetic Med》上在线发表一项关于糖尿病有关的主要下肢截肢发病率与糖尿病足护理密切相关,并随着护理的提高而改善的同行评议的研究。该研究调查英格兰西南地区糖尿病相关的下肢截肢发生率与足部护理的关系。 研究于英格兰在西南某一地区引入10项足部护理服务,从2007年开始,该区域足部溃疡发病率稳定,截肢发病率持续下降。引入的服务包括行政支持,标准化普通足部筛查,改善社区足病护理人员配备,医院多学科诊疗,有效护理路径,矫形师和审计的可用性。对该地区的糖尿病足部护理服务进行同行评估,以评估这些服务条款的执行情况,并将其与约克郡和亨伯尔公共卫生观察站医院提供的其他地区的主要截肢发病率统计数据进行比较进而提出了改善服务的建议。在2015年对服务供应和截肢发生率的变化进行了评估。 2013年的初步评估显示,糖尿病相关的3年截肢发生率与糖尿病足部护理服务的充分提供成负相关(P = 0.0024,调整后的R2 = 0.51)。2015年的重复评估发现,六名糖尿病足部护理员报告了两项或两项以上的足部护理服务改善,且结果有所改善。主要截肢发生率和服务提供之间的负相关关系在2012-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1760593, encodeId=68261e60593a2, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Nov 08 06:55:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970576, encodeId=69bf19e0576e4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Mon Jan 28 00:55:00 CST 2019, time=2019-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823446, encodeId=624d1823446c5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Jan 09 23:55:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638504, encodeId=9bc41638504c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Feb 12 16:55:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388181, encodeId=fb0f13881815e, content=<a href='/topic/show?id=e51454180b6' target=_blank style='color:#2F92EE;'>#截肢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54180, encryptionId=e51454180b6, topicName=截肢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1292500019, createdName=124984edm22暂无昵称, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608678, encodeId=d50116086e8a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 27 06:55:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]

相关资讯

糖尿病饮食定要加入的食物,这样吃才能吃好血糖,吃走致命并发症

近些年来,糖尿病已经成为了威胁全球公共健康的最大威胁之一,那么,糖尿病的管理就成为了值得认真探讨的话题。吃得好是糖尿病管理的重要组成部分,包括心脏健康的食物可以帮助进一步促进你糖尿病患者的健康。

这两个年龄段的女性须当心糖尿病“找茬儿”

提起糖尿病,大家都会想到老年人是高发人群。但是,随着生活水平提高及各种因素影响,近几年来不少年轻女性也悄悄患上了糖尿病。最新数据显示,北京市常住居民糖尿病患病率为9%。从性别分布看,男性患病率高于女性,但18至29岁及60岁以上的女性糖尿病患病率高于男性。年轻女性患糖尿病的概率为何高于同龄男性呢?火箭军总医院内分泌科主任李全民教授说,由于怀孕女性的激素出现多种变化,且饮食常常过于丰富,可引起胰岛素

Lancet Diabetes Endo:瑞典专家将糖尿病鉴定为5型,瞄准类型治疗才能一针见血!

长期以来糖尿病分为两大类:1型,主要影响不能生产胰岛素的年轻人和2型(以胰岛素抵抗为标志),或即使存在足够的胰岛素时,血糖(葡萄糖)也不能进入细胞并激活身体。

这例胸痛的罪魁祸首竟是……

患者,男性,18岁,因“胸痛、呼吸急促5小时”就诊。该患者入院5小时前无明显诱因下出现胸痛,胸痛部位以胸骨下段为主,呈持续性,较剧烈,无放射性感觉,伴明显呼吸急促,深呼吸及进食动作后明显,该患者无畏寒发热,无咳嗽咳痰咯血呼吸困难,无腹痛腹泻、恶心呕吐等伴随症状。

JCI:对脂肪组织的新探究揭开了糖尿病与心脏病的重要饮食诱因!

饮食诱发的糖尿病,肥胖和心脏病是全球死亡的主要原因。在为这些相关慢性疾病寻找新的治疗方法时,耶鲁的研究人员调查了一种名为ANGPTL4的蛋白质。蛋白质在调节脂蛋白代谢过程中起着重要作用,脂蛋白能够转运血液中的脂肪和脂质,并且与人类心脏疾病风险增加有关。

上海生科院等揭示代谢性手术治疗糖尿病的转归路径

近日,中国科学院上海生命科学研究院生物化学与细胞生物学研究所系统生物学重点实验室吴家睿、曾嵘、陈洛南研究组,与丹麦哥本哈根大学 Jens J. Holst 研究组合作的研究论文,以 Systems Signature Reveals Unique Remission-path of Diabetes Generated by Gastric Bypass Surgery 为题,发表在 EBioMe